On Monday, October 6, Heidi Health, an Australia-based healthcare technology company, announced that it had secured $65 million in Series B funding to accelerate the development of an Artificial Intelligence (AI) Care Partner for every clinician. Heidi Health develops AI medical scribe software for clinical documentation. 

Point72 Private Investments led the funding round with continued participation from investors Blackbird, Headline, and Latitude, the growth fund of Phoenix Court. This round values Heidi at $465 million, bringing the total funding to nearly $100 million.

The funding will be used to increase Heidi’s capacity by automating tasks such as clinical documentation, evidence search, and follow-up communications. According to the press release, Heidi will continue to grow its headcount, office locations, and local support in the USA, UK, and Canadian markets, while building on clinician-led adoption in France, Spain, Germany, Ireland, South Africa, Singapore, and Hong Kong.

“It is untenable that healthcare demand continues to rise while clinical time continues to shrink,” Dr Thomas Kelly, the CEO and co-founder of Heidi, said in a statement. “Building a sustainable healthcare system requires expanding clinical capacity without compromising clinician wellbeing or patient safety.”